Finch Therapeutics is a pioneering company based in Somerville, MA, specializing in the field of microbiome therapeutics. With a robust intellectual property estate and insights from human microbiota transplantation studies, Finch has established a leading portfolio of innovative microbiome assets that have potential applications in various product strategies and therapeutic areas.
In January 2023, Finch made the strategic decision to discontinue its Phase 3 trial of CP101 in recurrent C. difficile and instead focus on realizing the value of its IP estate and other assets. As a forward-thinking company, Finch is dedicated to exploring partnerships and opportunities to further advance its portfolio and contribute to the exciting new modality of the microbiome.
Generated from the website